Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Nintedanib

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

Product Specifications

CAS Number

656247-17-5

Product Name Alternative

BIBF 1120

UNSPSC

12352005

Hazard Statement

H301, H315, H318, H361, H372

Target

FGFR; PDGFR; VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BIBF-1120.html

Purity

99.97

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1NC2=CC(C(OC)=O)=CC=C2/C1=C(NC3=CC=C(N(C(CN4CCN(C)CC4)=O)C)C=C3)\C5=CC=CC=C5

Molecular Formula

C31H33N5O4

Molecular Weight

539.62

Precautions

H301, H315, H318, H361, H372

References & Citations

[1]Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 2008, 68 (12), 4774-4782.|[2]Roth GJ, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) . J Med Chem, 2009, 52 (14), 4466-4480.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

PDGFRα; PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4

Citation 01

ACS Omega. 2022 May 17;7 (21) :17658-17669.|Acta Pharmacol Sin. 2021 Dec;42 (12) :2058-2068.|Am J Respir Cell Mol Biol. 2019 Jul;61 (1) :74-85.|Am J Respir Cell Mol Biol. 2021 Jul;65 (1) :54-69.|Bioact Mater. 2023 Nov 22:33:262-278.|bioRxiv. 2024 Apr 21.|bioRxiv. 2024 Sep 13:2024.01.10.575008.|bioRxiv. 2025 Aug 09.|bioRxiv. 2025 March 19.|bioRxiv. 2025 Oct 24.|Br J Cancer. 2020 Mar;122 (7) :986-994.|Cell Chem Biol. 2022 Jul 21;29 (7) :1113-1125.e6.|Cell Death Dis. 2025 Apr 11;16 (1) :278.|Curr Eye Res. 2022 Dec;47 (12) :1578-1589.|Drug Dev Ind Pharm. 2024 Aug 7:1-16.|Eur J Drug Metab Pharmacokinet. 2021 Sep;46 (5) :625-635.|Eur J Pharmacol. 2024 Jun 5:972:176547.|Eur Respir J. 2025 Jan 9:2400615.|European J Org Chem. Nov 2022|Exp Eye Res. 2023 Apr:229:109431.|Exp Eye Res. 2025 Feb 12:110285.|FEBS Lett. 2024 Dec;598 (24) :3053-3070.|Folia Histochem Cytobiol. 2025;63 (2) :79-87.|Free Radic Biol Med. 2021 Aug 1:171:135-142.|Fundam Clin Pharmacol. 2021 Oct;35 (5) :919-929.|Harvard Medical School LINCS LIBRARY|Int Immunopharmacol. 2022 Dec;113 (Pt B) :109427.|Int J Mol Sci. 2022 Jul 25;23 (15) :8193.|Int J Mol Sci. 2023 Jan 12;24 (2) :1475.|Int J Ophthalmol. 2022 Jun 18;15 (6) :914-923.|Integr Biol (Camb) . 2022 Mar 21;14 (1) :1-12.|J Agric Food Chem. 2025 Apr 2;73 (13) :7774-7787.|J Cell Biochem. 2020 Mar;121 (3) :2343-2353.|J Ethnopharmacol. 2023 Oct 5:314:116633.|J Exp Med. 2025 Aug 4;222 (8) :e20241174.|J Mol Struct. 2016 Jul 5; 1115:171-179.|J Nat Prod. 2019 May 24;82 (5) :1331-1337.|J Ophthalmol. 2023 Apr 28:2023:7355039.|J Pharmacol Exp Ther. 2019 Jun;369 (3) :511-522.|J Photochem Photobiol B. 2016 Apr:157:70-6.|Life Sci. 2022 Nov 1:308:120950.|Lung Cancer. 2023 Jun:180:107219.|medRxiv. 2024 Jun 28.|Nat Mach Intell. 2020 Jun.|Nature. 2025 Nov 26.|Oncol Lett. 2024 Jan 25;27 (3) :123.|Oncol Rep. 2016 Dec;36 (6) :3123-3130.|Patent. US20220257531A1.|PLoS One. 2019 Aug 6;14 (8) :e0218632.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Research Square Print. September 14th, 2022.|Respir Investig. 2025 Jul 18;63 (5) :904-914.|Sci Adv. 2022 Jun 17;8 (24) :eabn4564.|Sci Rep. 2018 Jun 22;8 (1) :9540. |Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Sci Transl Med. 2022 Sep 28;14 (664) :eabo5070.|Small. 2024 Jul 25:e2403428.|SSRN. 2023 May 8.|SSRN. 2025 Aug 27.|Stem Cell Res Ther. 2020 Nov 25;11 (1) :496.|University of Pittsburgh. 2025.|Virology. 2023 Aug:585:205-214.|Am J Respir Cell Mol Biol. 2020 Feb;62 (2) :178-190.|Nano Today. 2024 Feb:54:102058.|Preprints. 2025 Apr 08.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

Human CHD8 activation kit by CRISPRa
GA111679 1 Kit

Human CHD8 activation kit by CRISPRa

Sign In for Pricing
View Details
Tissue FFPE Sections, Neurovascular bundle
CS808543 5x 5 µm

Tissue FFPE Sections, Neurovascular bundle

Sign In for Pricing
View Details
QK1 (QKI) Rabbit Polyclonal Antibody
TA361323 100 µL

QK1 (QKI) Rabbit Polyclonal Antibody

Sign In for Pricing
View Details
FGF1 (NM_001144935) Human Over-expression Lysate
LC428588 20 µg

FGF1 (NM_001144935) Human Over-expression Lysate

Sign In for Pricing
View Details
Tissue FFPE Sections, Prostate
CS701516 5x 5 µm

Tissue FFPE Sections, Prostate

Sign In for Pricing
View Details
Human LC3C (MAP1LC3C) activation kit by CRISPRa
GA118477 1 Kit

Human LC3C (MAP1LC3C) activation kit by CRISPRa

Sign In for Pricing
View Details